HH 003
Alternative Names: HH-003Latest Information Update: 11 Oct 2023
At a glance
- Originator Huahui Health
- Class Antiretrovirals; Antivirals; Monoclonal antibodies
- Mechanism of Action Hepatitis B surface antigen presurface protein 1 inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Hepatitis D
Most Recent Events
- 11 Oct 2023 Huahui Health completes a phase IIa trial in Hepatitis B (Combination therapy) in China (IV) (NCT05839639)
- 10 Oct 2023 Phase-Ib development is ongoing in Hepatitis B (In adults, Treatment-naive) in China (IV, Injection) (NCT05542979)
- 21 Jun 2023 Safety and efficacy data from a phase IIa trial in Hepatitis presented at the European Association for the Study of the Liver Congress 2023 (EASL-2023)